Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Chemokine signaling pathway 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
2 Chemokine signaling pathway 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
3 Chemokine signaling pathway 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
4 Chemokine signaling pathway 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
5 Chemokine signaling pathway 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
6 Chemokine signaling pathway 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
7 Chemokine signaling pathway 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
8 Epstein-Barr virus infection 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
9 Epstein-Barr virus infection 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
10 Epstein-Barr virus infection 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
11 Epstein-Barr virus infection 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
12 Epstein-Barr virus infection 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
13 Epstein-Barr virus infection 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
14 Epstein-Barr virus infection 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
15 Hepatitis B 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
16 Hepatitis B 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
17 Hepatitis B 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
18 Hepatitis B 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
19 Hepatitis B 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
20 Hepatitis B 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
21 Hepatitis B 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
22 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
23 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
24 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
25 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
26 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
27 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
28 Human T-cell leukemia virus 1 infection 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
29 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
30 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
31 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
32 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
33 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
34 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
35 JAK-STAT signaling pathway 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
36 Measles 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
37 Measles 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
38 Measles 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
39 Measles 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
40 Measles 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
41 Measles 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
42 Measles 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
43 Necroptosis 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
44 Necroptosis 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
45 Necroptosis 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
46 Necroptosis 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
47 Necroptosis 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
48 Necroptosis 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
49 Necroptosis 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
50 Non-small cell lung cancer 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
51 Non-small cell lung cancer 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
52 Non-small cell lung cancer 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
53 Non-small cell lung cancer 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
54 Non-small cell lung cancer 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
55 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
56 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
57 Pathways in cancer 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
58 Pathways in cancer 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
59 Pathways in cancer 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
60 Pathways in cancer 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
61 Pathways in cancer 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
62 Pathways in cancer 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
63 Pathways in cancer 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
64 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
65 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
66 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
67 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
68 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
69 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
70 PI3K-Akt signaling pathway 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
71 Primary immunodeficiency 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
72 Primary immunodeficiency 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
73 Primary immunodeficiency 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
74 Primary immunodeficiency 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
75 Primary immunodeficiency 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
76 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
77 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
78 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
79 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
80 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
81 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
82 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
83 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
84 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
85 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
86 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
87 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
88 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
89 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
90 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
91 Th1 and Th2 cell differentiation 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
92 Th17 cell differentiation 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
93 Th17 cell differentiation 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
94 Th17 cell differentiation 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
95 Th17 cell differentiation 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
96 Th17 cell differentiation 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
97 Th17 cell differentiation 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
98 Th17 cell differentiation 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
99 Viral carcinogenesis 💬
1件: JAK3 💬 Delgocitinib 💬 Delgocitinib 1件: 50 💬
100 Viral carcinogenesis 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
101 Viral carcinogenesis 💬
1件: JAK3 💬 Gusacitinib 💬 Gusacitinib 1件: 49 💬
102 Viral carcinogenesis 💬
1件: JAK3 💬 Peficitinib 💬 Peficitinib 1件: 46 💬
103 Viral carcinogenesis 💬
1件: JAK3 💬 Ritlecitinib tosylate 💬 Ritlecitinib 3件: 46, 96, 97 💬
104 Viral carcinogenesis 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
105 Viral carcinogenesis 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬